Dunliang Ma

Dunliang Ma

Auto-generated profile, based on publicly available information

Dunliang Ma

Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ZHZehan Huang
Zehan Huang
QWQiheng Wan
Qiheng Wan
YZYaoJun Zhang
YaoJun Zhang
FHFeiHuang Han
FeiHuang Han
DMDunLiang Ma
DunLiang Ma
BZBin Zhang
Bin Zhang

16 March 2026 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
SWShaoyu Wu
Shaoyu Wu
FHFeihuang Han
Feihuang Han
ZQZheng Qiao
Zheng Qiao
SYSheng Yuan
Sheng Yuan
XBXiaohui Bian
Xiaohui Bian
DMDunliang Ma
Dunliang Ma
Background: Atherosclerosis is a chronic inflammatory disease characterized by lipid-driven immune dysregulation. Argininosuccinate synthase 1 (ASS1) has been implicated in macrophage inflammation, yet its precise mechanistic role in foam cell-mediated vascular injury during atherosclerosis remains unclear. This study investigates whether ASS1 promotes disease progression via the NLRP3/IL-33/ST2 axis. Methods: An in vitro foam cell model was established using phorbol 12-myristate 13-acetate (PMA)-differentiated U937 macrophages treated with oxidized low-density lipoprotein (ox-LDL). The role of ASS1 was assessed via knockdown (si-ASS1) and overexpression (ASS1 overexpression) plasmids. Co-culture systems with human umbilical vein endothelial cells (HUVECs) and human aortic vascular smooth muscle cells (HAVSMCs) were used to evaluate endothelial apoptosis and VSMC proliferation/migration. In vivo, atherosclerosis was induced in apolipoprotein E‑deficient (ApoE)-deficient mice via a 12-week high-fat diet, and ASS1 expression was modulated using AAV9 vectors. Molecular analyses included ROS detection, enzyme-linked immunosorbent assay (ELISA), qPCR, western blot, and immunofluorescence. Plaque burden was assessed via Oil Red O staining. Results: Ox-LDL treatment significantly upregulated ASS1 expression in U937-derived foam cells. ASS1 overexpression enhanced intracellular ROS production, NLRP3 inflammasome activation, STAT3 phosphorylation, and IL-33 secretion. These effects were reversed by ASS1 knockdown. Rescue experiments demonstrated that STAT3 is required for ASS1-mediated NLRP3 activation and IL-33 upregulation. ASS1 altered IL-33 receptor ST2 signaling by increasing the soluble decoy isoform (sST2) and decreasing the membrane-bound signaling isoform (ST2L). In co-culture, ASS1-overexpressing foam cells promoted HUVEC apoptosis (via mitochondrial pathway) and HAVSMC proliferation, migration, and dedifferentiation. NLRP3 overexpression alone mimicked the pro-inflammatory effects of ASS1 and reversed the anti-inflammatory effects of ASS1 knockdown. In vivo, ASS1 knockdown in ApoE-/- mice reduced plaque lipid deposition, serum levels of IL-33 and IL-1β, and vascular expression of NLRP3 and p-STAT3, while ASS1 overexpression exacerbated these parameters. Conclusions: ASS1 drives atherosclerosis by activating the STAT3/NLRP3 inflammasome axis, shifting the IL-33/ST2 balance toward a pro-inflammatory state, and amplifying foam cell–mediated endothelial injury and smooth muscle cell dysfunction. Targeting ASS1 may offer a novel therapeutic strategy for inflammatory vascular disease.

Verified
Journal Article
Open access
PDF file
XHXingjie Huang
Xingjie Huang
DHDan Hu
Dan Hu
QWQiheng Wan
Qiheng Wan
HYHUANG Yu-qing
HUANG Yu-qing
DMDunliang Ma
Dunliang Ma
SWSong Wen
Song Wen
Background: Septal collateral channels (CCs) are generally preferred for retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI) because epicardial CC injury may result in hemopericardium and cardiac tamponade. However, comparative evidence on the procedural safety and long-term clinical outcomes of epicardial versus septal CC use remains limited. Methods: We retrospectively analyzed 750 patients who underwent elective retrograde CTO PCI from January 2011 through April 2023. The primary procedural safety outcome was periprocedural pericardial effusion. The primary long-term outcome was major adverse cardiovascular events (MACEs), defined as all-cause death, nonfatal myocardial infarction, stroke, or unplanned revascularization. Multivariable logistic and Cox regression models were used to evaluate these outcomes. Results: 544 patients underwent retrograde CTO PCI through a septal CC and 206 through an epicardial CC. Pericardial effusion (7.3% vs. 1.7%; p < 0.001) and pericardiocentesis (5.3% vs. 1.1%; p = 0.001) were more frequent with epicardial CC use. CC wire crossing success (90.8% vs. 94.5%; p = 0.067), retrograde technical success (87.9% vs. 90.1%; p = 0.40), and overall recanalization success (90.3% vs. 91.0%; p = 0.80) did not differ significantly. Epicardial CC use was associated with higher odds of pericardial effusion (OR 5.60, 95% CI 2.26–14.70, p < 0.001). During a median follow-up of 1039 days, MACE occurred in 15.0% and 16.5% of the epicardial and septal CC groups, respectively (HR 1.10, 95% CI 0.71–1.70, p = 0.659). Conclusions: Epicardial CC use was associated with more periprocedural pericardial effusion than septal CC use. No statistically significant differences in technical success or long-term MACE were detected; these findings do not establish equivalence and are subject to anatomical selection and residual confounding.

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
XWXinyi Wang
Xinyi Wang
QSQiqi Song
Qiqi Song
QZQingqing Zhang
Qingqing Zhang
XLXinyi Li
Xinyi Li
JWJiaqi Wang
Jiaqi Wang
LJLei Jiang
Lei Jiang
Background: In cardiovascular pathology, both direct bilirubin (DBIL) and high‐density lipoprotein cholesterol (HDLC) have been associated with adverse clinical outcomes. However, the prognostic significance of these biomarkers in the context of dilated cardiomyopathy (DCM) remains unclear. To address this gap, this study conducted a retrospective analysis to evaluate the prognostic value of the DBIL/HDLC ratio in patients diagnosed with DCM. Methods and Results: A total of 986 consecutive DCM patients were retrospectively enrolled from January 2010 to December 2019 and divided into two groups based on the DBIL/HDLC ratio cut‐off value: ≤ 4.45 ( n = 483) and > 4.45 ( n = 503). Patients with lower DBIL/HDLC (≤ 4.45) experienced lower in‐hospital mortality, long‐term mortality, and major adverse clinical events (MACEs) (0.8%, 32.9%, and 12.2%, respectively) compared to those with higher DBIL/HDLC (> 4.45) (6.4%, 59.1%, and 16.7%, respectively). Multivariate analysis identified DBIL/HDLC as an independent risk factor for long‐term mortality (odds ratio: 1.026; 95% confidence interval (CI): 1.005–1.048; p = 0.016) and all‐cause mortality over a median follow‐up of 67 ± 1.8 months (hazard ratio: 1.011; 95% CI: 1.005–1.018; p < 0.001). The receiver operating characteristic curve showed good discrimination for long‐term mortality (area under the curve (AUC): 0.675; 95% CI: 0.692–0.708; p < 0.001). The Kaplan–Meier survival analysis demonstrated a better prognosis for patients with DBIL/HDLC ≤ 4.45 (log‐rank χ 2 = 40.356, p < 0.001). Furthermore, the impact of additional variables on the results was investigated by a subgroup analysis. Conclusion: The DBIL/HDLC ratio could serve as a simple and cost‐effective tool for evaluating prognosis in DCM.

Verified
Journal Article
Open access
PDF file
QWQiheng Wan
Qiheng Wan
SWSong Wen
Song Wen
JXJiquan Xiao
Jiquan Xiao
FHFeihuang Han
Feihuang Han
ZHZehan Huang
Zehan Huang
BZBin Zhang
Bin Zhang
Introduction: The uric acid-to-albumin ratio (UAR) is a novel cardiovascular biomarker, but its prognostic value in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) remains unknown. Materials and Methods: This retrospective study enrolled 1513 consecutive patients who underwent successful CTO-PCI at a single center from February 2011 to December 2023. Patients were stratified by baseline UAR tertiles. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), and the secondary endpoint was all-cause mortality. Multivariable Cox regression and restricted cubic spline (RCS) analyses were performed. Results: During a median follow-up of 810 days, patients in the highest UAR tertile had significantly higher rates of MACCE (18.5%, 10.1%, and 7.5% across tertiles; p < 0.001) and all-cause mortality (10.7%, 3.8%, and 2.0%; p < 0.001). After multivariable adjustment, each one-unit increase in UAR was associated with a 6% higher risk of MACCE (HR 1.06; 95% CI 1.02–1.10; p = 0.002) and a 9% higher risk of all-cause mortality (HR 1.09; 95% CI 1.04–1.14; p < 0.001). Patients in the highest UAR tertile had significantly increased risks of MACCE (HR 1.90; 95% CI 1.25–2.90; p = 0.003) and all-cause mortality (HR 3.40; 95% CI 1.62–7.12; p = 0.001) compared with those in the lowest UAR tertile. RCS analysis showed significant overall associations between UAR and both MACCE and all-cause mortality, with no significant evidence of nonlinearity. Conclusions: Elevated baseline UAR was independently associated with long-term MACCE and all-cause mortality after successful CTO-PCI. These findings support UAR as a readily available prognostic marker but do not establish causality or support UAR-guided therapeutic decision-making. Prospective studies are needed for validation.